|Chemical and physical data|
|Molar mass||g·mol−1 409.92|
|3D model (JSmol)|
Balovaptan (INN; developmental code name RG7314), is a selective small molecule antagonist of the vasopressin V1A receptor which is under development by Roche for the treatment of autism. As of February 2019, it is in phase III clinical trials for this indication. On January 29, 2018, Roche announced that the US Food and Drug Administration (FDA) had granted Breakthrough Therapy Designation for balovaptan in individuals with autism spectrum disorder (ASD). The FDA granted this based on the results of the VANILLA (Vasopressin ANtagonist to Improve sociaL communication in Autism) study. Another study (aV1ation) is currently recruiting participants.
- "Roche - Pipeline". 2014. Retrieved 2014-08-01.
- A Study of RG7314 to Investigate Efficacy and Safety in Individuals With Autism Spectrum Disorders, at ClinicalTrials.gov; retrieved February 6, 2018
- "FDA grants Breakthrough Therapy Designation for Roche's balovaptan in autism spectrum disorder". 2018-01-29. Retrieved 2018-02-06.
- "Aviation Study". www.theaviationstudy.com. Retrieved 2019-02-07.
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|